Impiego di eritropoietina alfa nei programmi di chemioterapia ad alte dosi

Translated title of the contribution: Epoetin alpha and high-dose chemotherapy

Marco Danova, Massimo Aglietta, Luca Pierelli, Silvia Ferrari, Alessandro Perillo, Giovanni Scambia, David Henry

Research output: Contribution to journalArticlepeer-review


Epoetin (Epo) is physiologically present in the human body, stimulating erythropoiesis from bone marrow. Anemia is observed in cancer patients submitted to high-dose chemotherapy (HDCT), mainly caused by myelosuppression. Epoetin alfa has been widely used to treat the anemia that develops in the HDCT setting. Controlled studies in patients with hematologic malignancies or solid tumors who received Epo following HDCT have shown a decreased red blood cell transfusion requirement at least in patients receiving allogeneic bone marrow transplantation (BMT), while results in patients receiving autologous BMT have been disappointing. The administration of Epo before HDCT, in a period when bone marrow is still responsive to growth factors, may represent a new strategy aimed at decreasing the degree of anemia in these patients. A combination of granulocyte-colony stimulating factor and Epo has proved to be effective in mobilizing stem cell and committed myelold/erythroid precursors.

Translated title of the contributionEpoetin alpha and high-dose chemotherapy
Original languageItalian
Pages (from-to)681-689
Number of pages9
JournalRecenti Progressi in Medicina
Issue number12
Publication statusPublished - Dec 2000

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Epoetin alpha and high-dose chemotherapy'. Together they form a unique fingerprint.

Cite this